



PARIS

FAST-TRACK CITIES 2024

13-15 October 2024 | Maison de la Mutualité, Paris

Awareness and use of oral PrEP and the intention to use long-acting PrEP in 6 European Fast Track Cities (FTC) & 1 capital city – a geo-spatial gap analysis based on data from the PROTECT survey

Authors: Johann Kolstee¹; Haoyi Wang¹; Hanne Zimmermann¹; Melanie Schroeder²; Ama Appiah²; Ana Milinkovic²; Supriya Sarkar³; Kai Jonas¹

Affiliations:

¹ Department of Work and Social Psychology, Maastricht University, Maastricht, The Netherlands

² ViiV Healthcare, London, UK

³ ViiV Healthcare, Durham, USA



Rationale for a city level analysis



- Data (pharmacy/registry) often only available on a national level
- A cities approach is useful because:
 - Tendency for MSM to cluster in urban centres
 - Engagement of key populations, like MSM, should be locally driven
 - Governments globally have continued to devolve health responsibilities to local health districts
 - Access to PrEP often differs between cities
 - Large capital cities are often testing grounds for a more national approach to innovative prevention tools.
- Understanding the PrEP cascade is critical for improving HIV prevention
 - Awareness > Use of oral PrEP > Interest in LA-PrEP

PROTECT - FTC Cities Analysis

Objective: To investigate the directionality of gaps in the PrEP cascade

- Key variables of interest:
 - PrEP awareness
 - Oral PrEP use
 - Intention to use LA-PrEP
- Data from 2,074 Urban European CMSM included
- Cities included in this analysis:
 - FTC: Amsterdam, Berlin, Dublin, London, Madrid, Paris
 - Other: Rome

What was the PROTECT Survey?

The PROTECT Survey was:


- An online cross-sectional survey
- Conducted in 21 European countries
- Engaged multiple key populations (MSM, Hetero, Trans*)
- Tailored to key populations and key languages
- Designed collaboratively with research experts and community
- Partly funded by ViiV Healthcare
- **Primary study objective** = to close knowledge gaps related to the introduction of injectable long-acting cabotegravir (LA-PrEP) for PrEP in Europe



Key Demographics

14.330 cisgender men who have sex with men (CMSM) participated


- Median age of 40 (IQR 32-49)
- Mostly gay (84%)
- Highly educated (>70% had a bachelor or above)
- Mostly employed (77.8%)
- Good representation of CMSM with a migration background (23.5%)
- 45% current oral PrEP users
- 49% were PrEP naive




Key Measures

- Assessment of PrEP awareness
 - 1-item assessment
 - “Do you know what PrEP is?”
 - (Yes/No/Unsure)
- Assessment of Oral PrEP use
 - 1-item assessment
 - “Are you currently using oral PrEP?”
 - (Yes/No)
- Assessment of Intention to use LA-PrEP:
 - 1-item assessment
 - “How likely are you to start using LA-PrEP every 2 months if it is available to you?”.
 - Responses given on a 5-point Likert scale
 - 1 (Extremely unlikely) to 5 (Extremely likely)
 - Participants who scored 4 or 5 on the scale were classified as showing intention to use LA-PrEP


Results – Amsterdam & Paris



Results – Dublin & London



Results – Berlin, Madrid & Rome



Data comparison – Current Oral PrEP Use

City	PROTECT Current oral PrEP use among MSM	Reference Current oral PrEP use among MSM	Comments
Amsterdam	70.04%	53%	<ul style="list-style-type: none"> https://www.sciencedirect.com/science/article/pii/S0264410X23014494?via%3Dihub Amsterdam Cohort Studies 2022
Paris	68.2%	9.2%-20%	<ul style="list-style-type: none"> https://www.tandfonline.com/doi/abs/10.1080/09540121.2020.1739219 https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.26089 EMIS 2017
London	76.3%	74%	<ul style="list-style-type: none"> https://www.gov.uk/government/statistics/hiv-annual-data-tables/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2023-report#pre-exposure-prophylaxis-prep Among GBMSM with PrEP need, the proportion who initiated or continued PrEP
Dublin	56.54%		<ul style="list-style-type: none"> Estimated total initiations of oral PrEP: 8,418 https://www.prepwatch.org/countries/ireland/
Madrid	31.71%	44.8%	<ul style="list-style-type: none"> Reference neighbouring region Castilla y Leon https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/PrEP/Informe_SIPrEP_nov_19_mayo_23.pdf
Rome	25.9%		<ul style="list-style-type: none"> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335444/ Estimated total initiations of oral PrEP: 11,665
Berlin	76.56%	40-55%	<ul style="list-style-type: none"> https://web.archive.org/web/20210428202036id_/https://assets.researchsquare.com/files/rs-156075/v1/2bc653d4-08a3-4e61-b752-990bdde3f13d.pdf 2021

Potential Implications

- In Amsterdam, Dublin, London, Paris, Madrid and Rome
 - Population level PrEP use could potentially be increased by the introduction of LA-PrEP
- In Berlin:
 - Intention to use LA-PrEP lower than the proportion of current oral PrEP users
 - The roll out of oral PrEP may have consequences on the uptake of LA-PrEP
- In Madrid and Rome:
 - Lower oral PrEP awareness and much lower oral PrEP use than other cities
 - PrEP uptake gaps
 - Greater access to oral PrEP needed to increase HIV prevention coverage
 - LA-PrEP if made available could support greater population level HIV prevention coverage

Results Summary

- **PrEP awareness** - high in all cities
 - *(lowest Rome 84%)*
- **Oral PrEP use** - Majority of MSM in most cities already on oral PrEP
 - *(except Rome 26%, and Madrid 32%)*
- **Intention to use LA-PrEP** - Over $\frac{3}{4}$ of MSM in most cities intend to use LA-PrEP when it is made available
 - *(except Berlin 59%, and Rome 55%)*
- **Current PrEP users show higher interest in LA-PrEP than PrEP naïve individuals** – Found in all 7 cities

Thank you

Further Information

Project website: <https://protect-study.eu/>

Contact Information

- Prof. Dr. Kai J. Jonas
Email: kai.jonas@maastrichtuniversity.nl
- Dr. Johann Kolstee
Email: johann.kolstee@maastrichtuniversity.nl